S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Stock market today: Asia stocks rise follow Wall Street climbs to more all-time highs
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Stock market today: Asia stocks rise follow Wall Street climbs to more all-time highs
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Stock market today: Asia stocks rise follow Wall Street climbs to more all-time highs
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Stock market today: Asia stocks rise follow Wall Street climbs to more all-time highs
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck

Revance Therapeutics (RVNC) Short Interest Ratio & Short Volume

$7.14
+1.48 (+26.15%)
(As of 02/29/2024 ET)

Revance Therapeutics Short Interest Data

Current Short Volume
12,340,000 shares
Previous Short Volume
12,650,000 shares
Change Vs. Previous Month
-2.45%
Dollar Volume Sold Short
$68.86 million
Short Interest Ratio / Days to Cover
8.5
Last Record Date
February 15, 2024
Outstanding Shares
87,810,000 shares
Percentage of Shares Shorted
14.05%
Today's Trading Volume
7,064,249 shares
Average Trading Volume
1,715,603 shares
Today's Volume Vs. Average
412%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Revance Therapeutics ?

Sign up to receive the latest short interest report for Revance Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

RVNC Short Interest Over Time

RVNC Days to Cover Over Time

RVNC Percentage of Float Shorted Over Time


Revance Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
2/15/202412,340,000 shares $68.86 million -2.5%N/A8.5 $5.58
1/31/202412,650,000 shares $63.63 million -14.6%N/A7.7 $5.03
1/15/202414,810,000 shares $87.97 million +2.9%N/A9 $5.94
12/31/202314,390,000 shares $126.49 million +16.1%N/A8.4 $8.79
12/15/202312,400,000 shares $100.19 million -5.1%N/A7.3 $8.08
11/30/202313,070,000 shares $88.48 million -10.7%N/A6.2 $6.77
11/15/202314,630,000 shares $102.70 million +13.2%N/A7.1 $7.02
10/31/202312,930,000 shares $102.02 million -11.2%N/A6.5 $7.89
10/15/202314,560,000 shares $125.80 million -8.5%N/A7.5 $8.64
9/30/202315,910,000 shares $182.49 million +12.0%N/A8.8 $11.47
9/15/202314,200,000 shares $238.56 million -0.8%N/A7.9 $16.80
8/31/202314,310,000 shares $252.29 million No ChangeN/A10.2 $17.63
8/15/202314,310,000 shares $269.03 million +1.4%N/A10.5 $18.80
7/31/202314,120,000 shares $333.66 million +8.3%N/A10.1 $23.63
7/15/202313,040,000 shares $293.53 million -13.1%N/A10.1 $22.51
6/30/202315,000,000 shares $379.65 million +3.0%N/A11.1 $25.31
6/15/202314,560,000 shares $417.87 million -3.8%N/A11.2 $28.70
5/31/202315,130,000 shares $462.37 million +2.8%N/A11.8 $30.56
5/15/202314,720,000 shares $498.42 million +4.9%N/A10.8 $33.86
4/30/202314,030,000 shares $446.57 million +7.0%N/A11.1 $31.83
4/15/202313,110,000 shares $398.68 million +1.5%N/A10.1 $30.41
3/31/202312,920,000 shares $416.15 million +3.5%N/A8.3 $32.21
3/15/202312,480,000 shares $382.51 million +2.5%N/A7.9 $30.65
2/28/202312,180,000 shares $422.65 million +10.9%N/A7.9 $34.70
2/15/202310,980,000 shares $364.65 million -4.7%N/A7.5 $33.21
1/31/202311,520,000 shares $399.51 million -12.6%N/A7.6 $34.68
1/15/202313,180,000 shares $367.99 million +0.9%N/A8.7 $27.92
12/30/202213,060,000 shares $241.09 million +29.4%N/A9 $18.46
12/15/202210,090,000 shares $216.94 million -0.1%N/A7.9 $21.50
11/30/202210,100,000 shares $219.27 million -1.4%N/A6.6 $21.71
11/15/202210,240,000 shares $243.30 million +7.1%N/A6.2 $23.76
10/31/20229,560,000 shares $213.28 million +0.4%14.0%6 $22.31
10/15/20229,520,000 shares $238.95 million +1.6%13.9%6.4 $25.10
9/30/20229,370,000 shares $252.99 million +16.5%13.8%7 $27.00
9/15/20228,040,000 shares $212.34 million +3.7%11.8%6.9 $26.41
8/31/20227,750,000 shares $154.23 million -4.2%11.4%8.1 $19.90
8/15/20228,090,000 shares $178.95 million +7.9%11.9%10.9 $22.12
7/31/20227,500,000 shares $116.40 million +3.3%11.1%10.2 $15.52
7/15/20227,260,000 shares $109.41 million -3.7%10.7%10 $15.07
6/30/20227,540,000 shares $104.20 million +5.6%11.1%10 $13.82













RVNC Short Interest - Frequently Asked Questions

What is Revance Therapeutics' current short interest?

Short interest is the volume of Revance Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 15th, traders have sold 12,340,000 shares of RVNC short. Learn More on Revance Therapeutics' current short interest.

What is a good short interest ratio for Revance Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RVNC shares currently have a short interest ratio of 8.0. Learn More on Revance Therapeutics's short interest ratio.

Which institutional investors are shorting Revance Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Revance Therapeutics: Citadel Advisors LLC, Concourse Financial Group Securities Inc., Simplex Trading LLC, Wolverine Asset Management LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Revance Therapeutics' short interest increasing or decreasing?

Revance Therapeutics saw a decline in short interest in February. As of February 15th, there was short interest totaling 12,340,000 shares, a decline of 2.5% from the previous total of 12,650,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Revance Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Revance Therapeutics: Wave Life Sciences Ltd. (2.53%), KalVista Pharmaceuticals, Inc. (12.35%), Terns Pharmaceuticals, Inc. (11.50%), Arbutus Biopharma Co. (2.20%), Avid Bioservices, Inc. (8.93%), Mersana Therapeutics, Inc. (5.88%), Larimar Therapeutics, Inc. (3.49%), Mereo BioPharma Group plc (2.22%), Theravance Biopharma, Inc. (19.31%), LianBio (0.54%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Super Micro Computer, Inc. ($5.32 billion), T-Mobile US, Inc. ($4.38 billion), General Motors ($3.76 billion), Occidental Petroleum Co. ($3.08 billion), Charter Communications, Inc. ($2.65 billion), Coinbase Global, Inc. ($2.62 billion), Tractor Supply ($2.52 billion), Moderna, Inc. ($2.19 billion), Rivian Automotive, Inc. ($1.84 billion), and Royal Caribbean Cruises Ltd. ($1.78 billion). View all of the most shorted stocks.

What does it mean to sell short Revance Therapeutics stock?

Short selling RVNC is an investing strategy that aims to generate trading profit from Revance Therapeutics as its price is falling. RVNC shares are trading up $1.48 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Revance Therapeutics?

A short squeeze for Revance Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RVNC, which in turn drives the price of the stock up even further.

How often is Revance Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RVNC, twice per month. The most recent reporting period available is February, 15 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:RVNC) was last updated on 3/1/2024 by MarketBeat.com Staff